SCHOLAR ROCK HOLDING CORPORATION Cash and Cash Equivalents
SCHOLAR ROCK HOLDING CORPORATION (SRRK) had Cash and Cash Equivalents of $437.09 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $437.09M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $430.54M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $323.53M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $286.77M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $437.09M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $430.54M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $323.53M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $286.77M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $152.93M 10-Q · filed 2026-08-06 |
| 2025-03-31 | $137.93M 10-Q · filed 2026-05-07 |
| 2024-12-31 | $177.88M 10-K · filed 2026-03-03 |
| 2024-09-30 | $76.39M 10-Q · filed 2025-11-14 |
| 2024-06-30 | $93.37M 10-Q · filed 2025-08-06 |
| 2024-03-31 | $91.98M 10-Q · filed 2025-05-14 |
| 2023-12-31 | $101.86M 10-K · filed 2025-02-27 |
| 2023-09-30 | $67.60M 10-Q · filed 2024-11-12 |
| 2023-06-30 | $108.06M 10-Q · filed 2024-08-08 |
| 2023-03-31 | $151.28M 10-Q · filed 2024-05-07 |
| 2022-12-31 | $103.28M 10-K · filed 2024-03-19 |
| 2022-09-30 | $133.07M 10-Q · filed 2023-11-07 |
| 2022-06-30 | $305.73M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $100.17M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $212.84M 10-K · filed 2023-03-07 |
| 2021-09-30 | $176.13M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $206.92M 10-Q · filed 2022-08-08 |
| 2021-03-31 | $159.11M 10-Q · filed 2022-05-16 |
| 2020-12-31 | $160.36M 10-K · filed 2022-03-07 |
| 2020-09-30 | $56.23M 10-Q · filed 2021-11-09 |
| 2020-06-30 | $115.13M 10-Q · filed 2021-08-10 |
| 2020-03-31 | $95.43M 10-Q · filed 2021-05-13 |
| 2019-12-31 | $36.31M 10-K · filed 2021-03-09 |
| 2019-09-30 | $32.64M 10-Q · filed 2020-11-09 |
| 2019-06-30 | $113.80M 10-Q · filed 2020-08-07 |
| 2019-03-31 | $67.00M 10-Q · filed 2020-05-07 |
| 2018-12-31 | $115.07M 10-K · filed 2020-03-12 |
| 2018-09-30 | $103.99M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $115.06M 10-Q · filed 2018-08-08 |
| 2017-12-31 | $56.46M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |